BackEntrada Therapeutics Overview

Entrada Therapeutics Total Assets

Track Entrada Therapeutics's total assets ($300M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$298.88M
↓ 33.40% YoYΔ $-149.91M vs prior year quarter

Peer trimmed avg / median

Loading

Entrada Therapeutics Total Assets History

Loading

Entrada Therapeutics vs. peers: Total Assets Comparison

Loading

Entrada Therapeutics Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Entrada Therapeutics (TRDA) FAQ

Entrada Therapeutics (TRDA) currently reports a total assets of $300M as of June 2026. That compares with $450M in the prior-year period — down 33.4% year over year. Use the charts on this page to explore Entrada Therapeutics's total assets history and peer comparisons.

Entrada Therapeutics's total assets decreased from $450M to $300M — a 33.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Entrada Therapeutics reported $300M in total assets as of June 2026. That compares with $450M in the prior-year period — down 33.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total assets of $300M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Entrada Therapeutics, and consider following TRDA for alerts when major investors trade the stock.